Business Wire

Everlight Electronics That Illegally Obtained LED Technology Was Charged

13.9.2018 16:00:00 EEST | Business Wire | Press release

Share

Seoul Semiconductor (KOSDAQ:046890), a leading global innovator of LED products and technology, has announced that the International Crimes 4 Team at the Gyeonggi Nambu Provincial Police Agency in Korea is expected to detain three individuals, “A” – a former Managing Director of Seoul Semiconductor, “B” and “C” – former employees of Seoul Semiconductor, who divulged automotive LED technology that cost KRW 560 billion and seven years in development to Everlight Electronics, a competitor of Seoul Semiconductor located in Taiwan.

The three individuals will be charged for violating the Act on Prevention of Divulgence and Protection of Industrial Technology, and the Unfair Competition Prevention and Trade Secret Protection Act, and forwarded for prosecution.

Moreover, the CEO of Everlight Electronics and Everlight itself, both liable for the technology divulgence, have been charged under the Act on Prevention of Divulgence and Protection of Industrial Technology.

A, a former Managing Director of Seoul Semiconductor, took umbrage during his salary negotiations and sought out new employment opportunities using technology illegally obtained from Seoul Semiconductor as leverage. During the course of his search, A agreed to join Everlight Electronics in Taiwan as a high-paid Vice President.

Furthermore, investigations revealed that A attempted to use the information he gleaned illicitly from Seoul Semiconductor to develop an LED product for automotive headlights. To expedite development, A offered B and C, both researcher and former subordinate of A at Seoul Semiconductor, salary increases of 200% each and new jobs at Everlight Electronics in return for technical data from Seoul Semiconductor.

B and C took out laptops from the company to show secret materials of Seoul Semiconductor to A, and browsed for the secret information using their laptops at home on weekends to avoid suspicion from their colleagues. B and C also took photos of the information and either sent them via SNS or delivered them in person at Everlight Electronics in Taiwan.

In particular, B and C learned that Seoul Semiconductor had filed an injunction lawsuit against A for prohibition of competitive transaction as he joined Everlight Electronics in Taiwan, and used aliases and fake business cards to avoid litigation. They even denied the fact they were under the employ of Everlight Electronics during the investigation.

However, facts of the case showed that B and C were offered twice their previous salaries at Seoul Semiconductor, residence fee, monthly a week-long holidays, and round-trip airfares, etc. from Everlight Electronics.

Seoul Semiconductor invests approximately 10% of its annual sales into development of LED technology. In 2011, it produced automotive LED the first in Korea. As a result of its endeavors, Seoul Semiconductor holds more than 12,000 patents, and has been listed as one of the top companies around the world in terms of Patent Power compiled by IEEE (Institute of Electrical and Electronics Engineers), a global technical professional organization for electronics and electrical based in the USA. Seoul Semiconductor is the fourth largest LED manufacturer globally. The global LED lighting market currently stands at KRW 37 trillion. However forecasts expect the sector to reach KRW 52 trillion moving forward.

Separate from this case, Seoul Semiconductor has filed lawsuits against Everlight Electronics in Taiwan for five LED patent infringements.

“We estimate that, if A, B, and C were not discovered and charged, it would have lost KRW 560 billion in research and development over a seven-year period, and encroached upon its sales which currently stands at KRW 1 trillion per year,” said Yong Tae Lee, compliance department executive vice president of Seoul Semiconductor.

“The Police will leverage all legal procedures to track down suspects who leak and divulge technology overseas, as in this case, even when said suspects flee the country. Also, it will cooperate with relevant authorities to enforce measures that will allow the Police to restrict imports/exports and prohibit entry of personnel from foreign corporations that engage in industrial espionage. Moreover, it will continue to work on recovering financial damages caused by the divulgence of technology,” said the Gyeonggi Nambu Provincial Police Agency.

Lawsuits for LED patent infringements against Everlight Electronics (“E”)

#   Case   Date & News Release
1

SSC v. E
(4)

May 2017  

In Germany, Seoul Semiconductor filed “two” patent infringement litigations against a distributor of Everlight products

2 Feb. 2018

Seoul Semiconductor wins patent litigation against Everlight in the UK and the UK court orders Everlight to pay significant Litigation costs to Seoul Semiconductor

3 Feb. 2018

In Italy, Seoul Semiconductor files a patent infringement litigation against a distributor of Everlight products

4 Jul. 2018

In Japan, Seoul Semiconductor files a patent infringement litigation against a distributor of Everlight products

5

Nichia v. E
(5)

Mar. 2016

In China, Nichia filed a patent infringement lawsuit against Everlight’s China subsidiary

6 Oct. 2016

The Japan court rules that distributors of Everlight products infringed Nichia’s patent

7 Nov. 2016

The German court grants preliminary injunctions against Everlight’s LED products for infringement of Nichia’s patent

8 May 2017

U.S. Federal Court affirms that Everlight infringed Nichia’s patent

9 Jul. 2017

The German court rules that Everlight’s German subsidiary infringed Nichia’s patent

10  

Bridgelux v. E
(1)

  Aug. 2017  

In U.S., Bridgelux files a patent Litigation against Everlight for infringement of 5 patents

 

* As a result of a lawsuit regarding the prohibition on the change of employment, which forbids a person from joining a competitor of his/her former employer for a set period of time (1~2 years) after termination, defendant A was ordered to pay KRW 100 million for violating his Non-competition agreement and joining Everlight Electronics, and a further KRW 2 million per day if A continues employment at Everlight Electronics. (Seoul Central District Court, April 2017).

About Seoul Semiconductor
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. To learn more, visit www.seoulsemicon.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Seoul Semiconductor Inc.
Jeonghee Kim, +82-70-4391-8311
jeonghee.kim@seoulsemicon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye